Formulation and stability of hospital preparation of 3,4-diaminopyridine capsules

Administration of 3,4-diamynopyridine (3,4-DAP) has been found to be effective in the symptomatic treatment of patients with Eaton-Lambert Myasthenic syndrome. A recent case of this syndrome in Val de Grace Military hospital led us to manufacture 3,4-DAP capsules. In agreement with good manufactoring processes, we have performed mass uniformity and content tests. Six different formulations were tested, starch maize and magnesium stearate have been validated as excipients. The stability study showed that the conservation was good even under extreme conditions. Clinical and electromyographic improvement seen in this patient suggests this preparation may be of benefit.